CLINICAL ROLE -
Deucravacitinib Improves Quality of Life, Response Rates in Adults With Active Psoriatic Arthritis
Results of the POETYK PsA-2 trial indicate deucravacitinib’s effectiveness at reducing the severity and burden of symptoms in patients with psoriatic arthritis.
Icotrokinra Demonstrates Meaningful Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Icotrokinra, an oral pill that blocks the IL-23 receptor, had a favorable safety profile in adults and adolescents 12 years and older with moderate-to-severe plaque psoriasis.
Risankizumab Significantly Reduces Severity of Psoriasis Symptoms
Compared to placebo, risankizumab significantly reduced symptom severity for patients with moderate to severe disease.
Ruxolitinib Cream Could Provide Relief in Children Impacted by Atopic Dermatitis
The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.
Risankizumab Demonstrated Superior to Apremilast for Patients With Moderate Psoriasis
This treatment improved the severity of symptoms in patients with scalp and nail psoriasis.
Upadacitinib Can Significantly Improve Clinical Outcomes in Patients With Atopic Dermatitis
Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
A New Study Finds That Ruxolitinib Cream 1.5% Is Effective for Most Patients With HS
The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.
Secukinumab May Significantly Reduce Inflammation in Patients With Hidradenitis Suppurativa
Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.
Advanced Hidradenitis Suppurativa Increasingly Associated with cSCC
In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.
Study: SB17 Shows Biosimilarity to Ustekinumab for Plaque Psoriasis
The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.
